Hansa Medical’s SEK 246 million rights issue fully subscribed
Important information
The information in this press release is not directed at persons located in Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea, Singapore, South Africa, Switzerland, the United States or any other country where the offer or sale of subscription rights, interim shares or new shares is not permitted. The information may not be published or distributed, directly or indirectly, in or into, any of the aforementioned countries or any other country where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, other offer documentation, registrations or other actions in addition to what follows from Swedish law. Nor may the information be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or gives cause to such requirements. Failure to comply with these instructions may result in a violation of the United States Securities Act of 1933, as amended (“Securities Act”) or laws applicable in other jurisdictions.
The information in this press release does not contain or constitute an invitation or an offer to acquire, sell, subscribe for or otherwise trade in shares, subscription rights or other securities in Hansa Medical AB. No subscription rights, interim shares or new shares will be registered under the Securities Act or in accordance with any other rules or regulations in any other country than Sweden and may not be transferred or offered for sale in the United States or any country where such transfer or offer may be prohibited, or to persons resident in any such country or on account of such persons, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act or similar legislation in another country, respectively.
Hansa Medical’s rights issue with preferential rights has been subscribed at 100 percent of which 53 percent was subscribed through preferential rights. The rights issue comprises 6,482,400 shares at SEK 38 per share, which brings more than SEK 246 million before costs associated with the share issue. The proceeds will mainly be used to finance continued clinical development of IdeS and the company’s other research projects.
The board of Hansa Medical AB (publ) resolved, on February 22, 2015, pursuant to an authorization by the 2014 annual general meeting, on a rights issue of at most 6,482,400 shares with preferential rights at SEK 38 per share. The subscription period for the offer was between March 19 and April 2, 2015.
In total 3,444,862 shares were subscribed for using preferential rights, corresponding to approx. 53 percent of the number of shares in the rights issue. In addition, 862,694 shares were subscribed for without preferential rights, corresponding to approx. 13 percent of the number of shares in the rights issue. The remaining part was subscribed for by the underwriters.
“Hansa Medical is currently undergoing a very exciting development phase. The shares issue and the planned change of market place to Nasdaq Stockholm’s main market are important steps in Hansa Medical’s development. The size of the shares issue enables us to further develop our most important pharmaceutical candidate, IdeS, single-handedly. We are happy with the support from our existing shareholders and that we have received new shareholders, such as Rhenman & Partners, Hjärt-Lungfonden and other renowned long-term investors. We are now looking forward with excitement to developing the company further and we will shortly begin with additional clinical trials of IdeS“, says Göran Arvidson, acting CEO of the company.
The rights issue increases the number of Hansa Medical shares with 6,482,400 shares to a total amount of 32,412,003 shares. Following the rights issue, the share capital amounts to SEK 32,412,003. Paid subscribed shares, subscribed with preferential rights, are traded under the ticker HMED BTA on Nasdaq First North until April 16, 2015, after which they are expected to be converted into shares. The newly issued shares are expected to be traded on Nasdaq First North, starting on April 20, 2015.
The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on April 9, 2015 at 08.00 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CFO and acting CEO
Mobile: 46 706-33 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.
Tags: